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Juvenile myasthenia gravis (MG), defined as symptom onset before 
the age of 20, is generally less common than adult MG,1,2 and has 
been shown to have different sex and racial frequencies when white, 
African-American and Asian populations are compared.3 There are 
no data on juvenile MG from the African continent. 
One centre has described racial differences in the outcome 
of generalised MG among South Africans, finding that severe 
treatment-resistant extra-ocular muscle (EOM) paresis or 
ophthalmoplegia occurred almost exclusively in subjects of African 
genetic ancestry.4 A higher proportion of individuals who developed 
partial or complete ophthalmoplegia presented with MG symptoms 
at a young age.4
We present the data from 190 subjects with juvenile MG collected 
from 6 academic centres throughout South Africa, report the 
frequency of the ophthalmoplegic complication in ocular and 
generalised MG and outcome in response to treatment. 
Methods
The records of all patients up to June 2011 with a diagnosis of auto-
immune MG from 6 tertiary care hospitals across South Africa were 
analysed: Groote Schuur Hospital (GSH), Cape Town; Red Cross War 
Memorial Children’s Hospital (RCWMCH), Cape Town; Tygerberg 
Children’s Hospital (TCH), Cape Town; Chris Hani Baragwanath 
Hospital (BARA), Soweto; Steve Biko Academic Hospital (SBA), 
Pretoria; Universitas Hospital (UH), Bloemfontein.
The diagnosis of MG was based on fatiguable weakness, a positive 
response to cholinesterase inhibitors and a positive acetylcholine 
receptor (AChR) antibody test (>0.2 nmol/l)1 or a positive response 
to immunotherapy such as plasma exchange or intravenous 
immunoglobulin (IVIg) or oral prednisone. Where the AChR 
antibody test was not performed or the result unknown, but there was 
a clear response to immunosuppression, the subject was classified as 
having either ocular (see later) or generalised MG.
Subjects with probable congenital myasthenic syndromes, i.e. 
fatiguable weakness but without any of the other criteria listed above, 
were excluded from the analyses: GSH (4), RCWMCH (1), TCH (0), 
BARA (1), SBA (0), UH (0). Neonates born to mothers with MG who 
showed transient symptoms (neonatal myasthenia) were not included.
The diagnosis of ocular MG was applied to those subjects with 
MG symptoms confined to the ocular muscles for the duration of 
their clinic attendance. We followed the MG Foundation of America 
(MGFA) Task Force recommendations5 (see footnote, Table 1) to 
determine clinical grade at onset and the ‘post-intervention status’ 
to categorise therapeutic response; where centres did not use the 
MGFA categorisation, minimal manifestations status (MMS) was 
used to identify patients ‘in remission’ or without symptoms, MMS-0 
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there was a trend towards more remissions in the thymectomy 
group compared with the non-thymectomy group (p=0.057).
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maximum severity, or use of immunosuppression. However, 23% of 
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ophthalmoplegia as a complication of generalised MG (p=0.002).
Conclusion. Younger children developed ocular MG and older 
children generalised MG. Persistent ophthalmoplegia developing as 
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complication that causes significant morbidity is, as yet, unclear.
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refers to those without treatment, MMS-1 refers to cholinesterase 
inhibitors (pyridostigmine) only, MMS-3 refers to subjects also 
undergoing immunosuppressive therapies. Immunosuppressive 
therapies consisted of prednisone with or without steroid-sparing 
agents, intravenous immunoglobulin (IVIg) or plasma exchange. 
Among those subjects undergoing thymectomy, the delay in months/
years between symptom onset and thymectomy was documented, as 
was thymic histology.
Subjects from Cape Town had been followed up for the longest 
period due to the referral system between the paediatric units of 
TCH and RCWMCH and the MG clinic at GSH. Furthermore, a 
prospective observational database was established at GSH in 1996 
and updated 6-monthly, recording a quantified MG score on each 
patient, outcome and number of paralysed EOMs and treatment.4 
In 2010 the other centres were co-opted into assessing their own 
patient records, largely retrospectively, and documenting age at onset, 
Table 1. Clinical characteristics of juvenile-onset myasthenia gravis from 6 South African centres
GSH RCWMCH TCH BARA SBA UH
Total MG, N 77 28 14 53 8 10
AChR-ab+, N (%) 58 (76) 16 (59) 5 (42) 30 (86) 8 (100) 9 (90)
Ocular MG, N (%)
Female, N (%)
Onset, mean years (±SD)
5 (6)
0 (0)
11.4 (±5.9)
16 (57)
8 (50)
3.9 (±1.8)
9 (64)
7 (78)
3.8 (±2.0)
16 (30)
11 (69)
4.4 (±2.4)
4 (50)
3 (75)
7.5 (±3.0)
0 (0)
-
-
Generalised MG, N (%)
Females, N (%)
Onset, mean years (±SD)
1 - 11 years, N
12 - 20 years, N
72 (94)
52 (72)
14.0 (±4.0)
14
57
12 (43)
5 (45)
4.4 (±2.5)
12
0 (0)
5 (36)
4 (80)
5.2 (±3.7)
5
0 (0)
37 (70)
20 (54)
6.2 (±2.7)
37
0 (0)
4 (50)
3 (75)
6.0 (±0.8)
6
0 (0)
10 (100)
6 (60)
7.9 (±5.1)
4
3
MGFA diagnosis, N (%)
I
IIa,b
IIIa,b
IVa,b
V
14 (19)
30 (42)
12 (17)
8 (11)
8 (11)
4 (36)*
4 (36)
1 (9)
1 (9)
-
1 (20)
2 (40)
1 (20)
1 (20)
-
8 (23)
16 (46)
10 (29)
1 (3)
1 (3)
-
4 (100)
-
-
-
1 (10)
2 (20)
3 (30)
3 (30)
1 (10)
Median follow-up, years (IQR) 10.0 (4.0 - 17.0) 4.0 (0.8 - 6.9) 2.0 (0.2 - 2.0) 2.2 (1.0 - 5.5) 3.0 (2.4 - 3.3) 3.0 (1.3 - 6.0)
MGFA-max., N (%)
IIa,b
IIIa,b
IVa,b
V
Death due to MG, N (%)
32 (45)
7 (10)
4 (6)
27 (38)
0 (0)
6 (60)*
2 (20)
2 (20)
0 (0)
0 (0)
3 (60)
1 (20)
1 (20)
0 (0)
0 (0)
14 (40)
11 (31)
4 (11)
6 (17)
3 (9)
4 (100)
-
-
-
-
-
5 (50)
2 (20)
2 (20)
1 (10)
Thymectomies, N (%)
Thymomectomies, N (%)
47 (66)
2 (3)
1 (9)
0 (0)
0 (0)
0 (0)
5 (17)
0 (0)
0 (0)
0 (0)
4 (40)
1 (10)
Treatment, N (%)
CH only
+ Pred 
+ Pred + azathioprine
+ Pred + methotrexate
+ IVIg/plasma exchange
8 (11)†
17 (24)
45 (63)
9 (13)‡
15 (21)
6 (55)¶
1 (9)
3 (27)
1 (9)‡
2 (18)
1 (20)
3 (60)
0 (0)
1 (20)
1 (20)
15 (43)¶
16 (46)
2 (6)
5 (14)
2 (6)
0 (0)
2 (50)
2 (50)
0 (0)
0 (0)
0 (0)
1 (10)
8 (80)
3 (30)‡ 
6 (60)
MGFA-last follow-up,§  N (%)
MMS
I
IIa,b
IIIa,b
IVa,b
V 
34 (51)
11 (16)
20 (30)
1 (1)
1 (1)
0 (0)
4 (40)
0 (0)
5 (50)
1 (10)
0 (0)
0 (0)
3 (75)
1 (25)
0 (0)
0 (0)
0 (0)
0 (0)
15 (47)
0 (0)
14 (44)
3 (9)
0 (0)
0  (0)
0 (0)
0 (0)
4 (100)
0 (0)
0 (0)
0 (0)
5 (56)
0 (0) 
3 (33)
1 (11)
0 (0)
0 (0)
GSH = Groote Schuur Hospital; RCWMCH = Red Cross War Memorial Children’s Hospital; TCH = Tygerberg Children’s Hospital; BARA = Chris Hani Baragwanath Hospital; SBA = Steve Biko 
Academic Hospital; UH = Universitas Hospital. AChR-ab+ refers to acetylcholine receptor antibody-positive sera (denominator includes all who had the assay). MGFA clinical classification refers 
to I – ocular, II – mild weakness, III – moderate weakness, IV – severe weakness, V – intubation and (a) predominantly axial limb muscle weakness whereas (b) with prominent involvement of 
bulbar muscles. MMS = minimal manifestation status (see Methods).
*1 unknown.
†2 individuals were treated with cholinesterase inhibitors (CH) only for 5 and 7 years, respectively, and then initiated on prednisone (Pred).
‡
Mostly individuals who had not experienced steroid-sparing activity with azathioprine.
¶
3 individuals were treated with intravenous immunoglobulin (IVIg) when they presented in crisis and only received CH thereafter and 1 HIV-infected subject only received CH.
§Unknown outcomes or deaths are not reflected.
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presenting MGFA grade, maximum severity, duration of follow-
up, outcome on treatment and specifically paresis of EOMs and 
eyelids/ptosis. EOM paresis does not refer to the fatiguable weakness 
expected with MG but rather spontaneous and persistent pareses/
paralysis of one or more EOMs. If the EOMs could not be precisely 
examined and rated the investigators summarised these as partial (at 
least 6/12 (50%) of EOMs affected) or complete ophthalmoplegia (all 
12 EOMs affected, invariably with bilateral ptosis).4
We have grouped patients according to race, predominantly 
by self-reporting (GSH) or mother tongue (remainder), as the 
ophthalmoplegic MG complication was previously described to 
show significant racial bias in a GSH cohort.4 The study protocol was 
approved by the ethics committees of all the participating universities.
Statistical analyses
Normally distributed data were presented as means and standard 
deviations (SD) and non-normally distributed data by medians 
and interquartile ranges (IQR). As appropriate, the Student t-test, 
Mann-Whitney test, chi-square test (or Fisher’s exact test) were used 
to compare data. The Kruskal-Wallis one-way ANOVA was used 
to compare continuous variables not normally distributed for more 
than two groups, e.g. racial categories, and the Spearman rank-order 
correlation coefficient was used to assess relationships between 
ordinal variables between two groups. The MGFA and EOM grades 
were considered ordinal variables. The racial variation of EOMs or 
MGFA grades was assessed using the Kruskal-Wallis test. All analyses 
were two-sided and a p-value <0.05 was considered significant. 
Statistical analyses were done using STATISTICA 9 (Statsoft).
Results
The records of 190 juvenile MG patients who developed symptoms at 
a median age of 7 years (IQR 4 - 14, range 0.5 - 19.7) were assessed. 
The distribution of ages at onset showed two peaks corresponding to 
a pre-pubertal group (onset <12 years, N=126; 66%) with a mean age 
of 5.6 years (SD±2.9) and a post-pubertal group (N=64; 34%) with a 
mean age of 15.6 years (SD±2.2). Children with ocular MG presented 
at a younger age than those with generalised MG (p=0.0004) (Table 
1). Subjects presenting with generalised symptoms were diagnosed 
after a longer delay than those presenting with ocular symptoms 
(mean 1.2±2.1 v. 0.8±1.4 years, respectively; p=0.16). Patients were 
followed up for a median period of 4 years (IQR 1 - 4, range 0.2 - 44).
Additional auto-immune disease was found in 12 (6%) individuals 
(1 patient had 2 auto-immune diseases), including systemic lupus 
erythematosus (2), insulin-dependent diabetes mellitus (2), juvenile 
rheumatoid arthritis (1), vitiligo (4), thyroid disease (2), psoriasis 
(1) and alopecia areata (1). Nine individuals had family members 
with an auto-immune disease of which MG (4% of cohort) was the 
commonest (the mothers of 2 individuals had MG and a further 3 had 
a second/third-degree MG relative with MG). There was 1 individual 
each with additional epilepsy, neurofibromatosis and HIV infection. 
No individuals developed cancer.
Ocular MG
Fifty patients had ocular disease as the sole manifestation of MG, with a 
mean age at symptom onset of 5.1 years (SD±3.5). Children of African 
or recent African ancestry showed a trend towards developing ocular 
MG rather than generalised MG (p=0.056) when compared with those 
of European ancestry. Ocular MG was more frequent (N=47; 94%) 
in the pre-pubertal onset group (<12 years) than in those with post-
pubertal onset MG (N=3; 5%) (p<1×10-4). AChR antibody status was 
known in 42 of whom 26 (62%) were AChR antibody-positive. The 
median duration of follow-up was 1.5 years (IQR 0.8 - 4.0).
Forty-five per cent of the subjects were treated with cholinesterase 
inhibitors, while the remainder also received prednisone. The median 
time from symptom onset to initiating prednisone was 0.3 years 
(IQR 0.2 - 0.5). Remissions were obtained in 23 of 46 (50%), of 
whom 10 (20%) went into remission without using prednisone. 
Generally, remissions and functional improvement occurred among 
children of all races (p=0.17) and occurred irrespective of the use of 
immunosuppressive therapy (p=0.53).
Twenty-one (42%) of these children were followed up for ≥2 
years during which time the MG symptoms remained active and 
confined to the ocular muscles. Of these subjects, 8 had persistent 
partial ophthalmoplegia (6 - 10 EOMs paresed) and 2 had complete 
ophthalmoplegia with bilateral ptosis; all were of African genetic 
ancestry (p=0.006).
Generalised MG
One hundred and forty subjects had generalised MG and 
presented with symptoms at an older age (mean 10.2 years, 
SD±5.4). Twenty-nine (21%) presented with ocular symptoms 
but developed generalised disease soon thereafter. Indigenous 
African children developed MG symptoms at a younger age 
than those with recent African and European genetic ancestry 
(p≤1×10-4). The latency between symptom onset and diagnosis 
was on average 1.2 years (median 0.5; IQR 0.2 - 1.0). Of the 121 
available AChR antibody test results, 98 (81%) were positive, 
irrespective of race (p=0.36). The median duration of follow-up 
was 5 years (IQR 2 - 10).
Overall, the median MGFA grade at disease presentation was 
mild (grade 2; IQR 2 - 3), deteriorating to a maximum grade of 3 
or moderate disease severity (IQR 2 - 5) and improving to a final 
grade 1 (IQR 0 - 2), with 45% (60/133) in functional remission 
(minimal manifestation status). There was no racial difference 
in the MGFA grades at presentation or maximum severity but 
there was a difference in the final MGFA grade (p=0.044), likely 
a reflection of the persistent ophthalmopareses among children 
with African genetic ancestry (see later). Age at which symptoms 
started did not influence the final MGFA grade (p=0.81).
Fig. 1. Racial distribution of extra-ocular muscle (EOM) paresis as a 
complication of AChR antibody-positive generalised myasthenia gravis 
(MG). A histogram plot of EOM dysfunction in MG subjects followed 
up for at least 2 years and who had AChR antibody-positive MG. Racial 
classification according to the South African census groups (see Methods): 
B = indigenous African or black; M/A = mixed or recent African ancestry; 
W = white or European ancestry. N refers to full EOM movements but 
may have fatiguable weakness; paresed refers to 1 or more of the 12 EOMs 
showing paresis or ophthalmoplegia; complete refers to ophthalmoplegia of 
all 12 EOMs (χ2; p=0.003).
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Disease onset was more frequent before onset of puberty (57%). 
Post-pubertal MG tended to be more severe than pre-pubertal MG 
(p=0.08), with a higher proportion of older children developing at 
least one MG crisis (p=0.017) (Table 2).
Partial or complete ophthalmoplegia developing as a complication 
of generalised MG was observed in 32 children (23%), all of whom 
were of either African or recent African genetic ancestry. Fig. 1 
depicts the distribution of the number of extra-ocular muscles 
affected. The distribution of cases did not differ between the larger 
centres: combined Cape Town 27%; BARA 24%; combining SBA+UH 
22% (p=0.69). The presence of MG-associated ophthalmoparesis 
correlated significantly with the race of the child (p=0.002), but not 
with gender (p=0.86), age at symptom onset (p=0.94), latency before 
diagnosis (p=0.60), use of immunosuppressive therapy (p=0.34), or 
years before the initiation of immunosuppressive therapy (p=0.70). 
Most of the patients (75%) were noted to have ophthalmoplegia at the 
time of MG diagnosis, but unlike the remaining MG manifestations 
the ophthalmoplegia remained treatment-resistant. The remaining 
25% had some ocular MG manifestations at diagnosis, but only 
developed the complete ophthalmoplegia while being treated with 
immunosuppressive therapy.
Treatment and outcome
Immunosuppressive therapies were used in 83% of generalised 
MG cases, whereas 17% were treated symptomatically with 
pyridostigmine alone. The latency between diagnosis and initiation 
of immunosuppressive therapy was on average 1.7 years (median 0.5 
years, IQR 0.2 - 2.0). Twelve individuals (10%) achieved remissions 
without immunosuppressive therapy; 3 received IVIg after initially 
presenting in MG crisis, but subsequently improved and did not 
need further immunosuppression. Sixty-nine subjects (63% of those 
on immunosuppression) were also treated with steroid-sparing 
agents (see Table 1). Four patients (3%) died of a myasthenic crisis, 
of whom 2 were not treated with immunosuppressive therapies. An 
additional 2 subjects died of unrelated causes – 1 of HIV/AIDS and 
1 of ischaemic heart disease and arrhythmia, after 3 and 44 years of 
follow-up, respectively.
Of those with generalised MG, 43% underwent thymectomy, 
which was performed more frequently in older children (Table 2, 
p≤1×10-4); half underwent surgery within 1 year of symptom onset. 
Thymic histological findings were available in 54: 36 (67%) had 
thymic hyperplasia, 3 (2%) had thymoma and 12 (22%) were normal. 
The patients undergoing thymectomy had greater disease severity 
than those who did not have surgery (p=0.002), and showed a trend 
towards proportionately more remissions achieved (55% v. 38%; 
p=0.057).
Owing to increased severity of disease, post-pubertal children were 
more likely to receive immunosuppressive therapies or to undergo 
thymectomy. However, the proportions obtaining remissions were 
similar (p=0.24).
The effect of thymectomy on the long-term remission rate in 
juvenile generalised MG
Analysis of the clinical outcome of 46 subjects (5 being lost to follow-
up) diagnosed by one of three Cape Town clinics and followed 
up for a median of 7.5 years (range 0.3 - 44 years), shows that the 
thymectomy group had more severe disease (54% MGFA grade 
4 or 5) compared with the non-thymectomy group (19% MGFA 
grade 4 or 5). Thymectomy did not influence the development of 
MG-associated ophthalmopareses (p=0.57) or frequency of remission 
(p=0.51). Twenty (of whom 16 had thymectomy) diagnosed with MG 
prior to 2001 still attend the clinic with active MG.
Discussion
We present the first description of an African juvenile MG cohort.
Racial variation among juveniles with MG has been previously 
reported, with a very high incidence of ocular MG among Asian 
children.6 Interestingly, we show that children with African genetic 
ancestry, as opposed to European ancestry, also show a trend 
toward more ocular MG, with an age peak between 2 and 4 years.3 
Moreover, we show that a substantial proportion of children with 
generalised AChR antibody-positive MG develop severe, treatment-
resistant ophthalmoplegia associated with significant morbidity (Fig. 
1).4 Apart from an isolated Canadian case (1 of 25)7 and 2 Korean 
children (2 of 24),8 an hitherto unrecognised MG complication 
of ophthalmoplegia and ptosis was described in a cross-sectional 
analysis of South Africans with generalised MG attending one 
centre (Cape Town).4 In that report, 13 patients with African 
genetic ancestry developed complete ophthalmoplegia and bilateral 
ptosis, 7 having developed MG symptoms in childhood.4 We now 
present data to show that either partial or complete ophthalmoplegia 
occurs among 23% of South Africans with juvenile MG attending 
different centres across South Africa. All subjects had African genetic 
ancestry (either indigenous African or recent African ancestry). The 
majority of these children had already developed either partial or 
complete ophthalmoplegia at the time of generalised MG symptom 
Table 2. Comparison of pre-pubertal (<12 years) and post-pubertal (≥12 years) onset among generalised MG juveniles (N=140)*
Pre-pubertal Post-pubertal p-value
N (%) 79 (57) 61 (44)
Females, N (%) 45 (56) 45 (74) 0.041
AChR antibody-positive, N (%)* 53 (79) 46 (82) 0.680
Thymectomy, N (%) 17 (22) 44 (72) <1×10-4
Follow-up, median years (IQR) 5 (2 - 10) 9 (5 - 17) 0.019
No immunosuppressive therapy, N (%) 19 (24) 4 (7) <1×10-4
≥1 MG crisis, N (%) 22 (28) 27 (44) 0.047
MMS, N (%) 32 (41) 30 (49) 0.380
Partial/complete ophthalmoplegia, N (%) 24 (31) 12 (20) 0.180
Normal eye movements, N (%) 46 (59) 40 (68) 0.240
*Only those with known results included. MMS refers to minimal manifestations of MG (functional remission with or without treatment).
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presentation, whereas the remainder developed it after treatment 
initiation. Research into the molecular basis9 and the optimal 
management of this complication is ongoing.
Juvenile MG accounts for less than 10 - 15% of all MG cases, 
with an incidence of 1 - 5 per million per year.3 The incidence of 
juvenile MG in South Africa is expected to be similar although 
under-recognition of MG is likely where access to specialist services 
is poor.1 As has been reported from the First World, pre-pubertal 
children tended to have more ocular presentations whereas post-
pubertal cases were similar to adults with more generalised disease 
and female preponderance. The MGFA grades at presentation and 
frequency of AChR-positive generalised MG among this cohort were 
similar to other juvenile cohorts.3, 6,10 Remission rates in children are 
generally said to be high (11 - 37%).2,6,7,10 Our overall remission rate of 
45%, of whom approximately 10% went into spontaneous remission, 
is comparable. Compared with generalised disease, ocular MG 
showed more frequent remissions and more often without the use of 
immunosuppressive therapies.
Thymectomy for AChR antibody-positive generalised MG is 
generally thought to be beneficial.3 Sixty of the generalised MG 
subjects, of whom the majority were post-pubertal children with more 
severe disease, underwent thymectomy; the histological examination 
showed the expected preponderance of thymic hyperplasia.6 A 
previous report which suggested that African-American children 
had a lower remission rate after thymectomy (≈20%) compared 
with those of European ancestry (≈58%)9 is not supported by our 
data, which comprised predominantly children with African genetic 
ancestry (in whom there was ≈45% remission). Although we showed 
a trend towards more remissions after thymectomy (p=0.057), a 
sub-analysis of the Cape Town cohort with longer patient follow-up 
did not reveal a difference in remission rate between those that did 
and those that did not have thymectomy (p=0.51; data not shown). 
However, the benefit of thymectomy versus no thymectomy is being 
studied for the first time in a prospective multinational controlled 
trial, the results of which are eagerly awaited.11
Generally the therapeutic approach in cases of generalised MG 
does not differ from that of adult-onset MG.3 Prednisone is first-
line treatment in patients with symptoms who fail to respond to 
cholinesterase inhibitors (pyridostigmine).3,4 Azathioprine is the 
most commonly used steroid-sparing agent. While cyclosporine, 
mycophenolate mofetil or cyclophosphamide is second-line treatment 
elsewhere in the First World, we are increasingly using methotrexate, 
which has been shown to be cost-effective in adults with generalised 
MG12 and is frequently used in other juvenile auto-immune diseases.
Congenital myasthenic syndromes have been excluded from 
this analysis. Although ophthalmoplegia and ptosis may occur in 
congenital myasthenia they differ from acquired auto-immune MG 
described here, with the latter having circulating AChR antibodies and 
the non-ocular myasthenic manifestations responding significantly 
and appropriately to standard immunotherapy.
Although representing one of the largest published cohorts, there 
are a number of limitations to our study. Apart from Cape Town, data 
from other centres were retrospectively collected, albeit according to 
a study protocol. Further, the follow-up time was limited in many of 
the patients. The GSH cohort included fewer pre-pubertal patients, 
reflecting the fact that this hospital largely serves adults; the focus 
of the other five centres was on pre-pubertal subjects (Table 1). 
Nevertheless, the two larger centres (Cape Town and Soweto/BARA) 
reported similar frequencies of ophthalmoplegia.
In conclusion, the use of immunosuppression in juveniles with 
generalised MG not responding to pyridostigmine alone, is associated 
with a good remission rate.
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